153.96 0.00 (0.00%)
After hours: 6:08PM EDT
|Bid||154.56 x 800|
|Ask||154.60 x 800|
|Day's Range||150.89 - 155.13|
|52 Week Range||119.38 - 190.36|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||17.88|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||168.74|
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (LH), a leading global life sciences company, announced today an extension of their exclusive distribution agreement as well as an additional investment by LabCorp. The distribution agreement and LabCorp’s initial investment in OmniSeq’s Series B financing round were first announced in August 2017. The distribution agreement originally provided LabCorp with exclusive distribution rights for the OmniSeq Comprehensive and Immune Report Card clinical assays.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Envigo Laboratories Inc. New York, April 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Envigo Laboratories Inc. ("Envigo") and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Moody's Investors Service ("Moody's") placed the ratings of Envigo Laboratories Inc. under review for upgrade. Ratings under review for upgrade include the Caa2 Corporate Family Rating, Caa2-PD Probability of Default Rating, the B3 senior secured first lien credit facilities and Caa3 senior secured second lien credit facilities. The announced sale of Envigo's nonclinical contract research services business to LabCorp and the concurrent acquisition of LabCorp's US research models and services business is credit positive given the improvement in liquidity due to net proceeds to be received of $485 million.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Laboratory Corporation of America Holdings and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, we'l...
BURLINGTON, N.C. & EAST MILLSTONE, N.J.-- -- LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United States, combining two complementary businesses into a new comprehensive ...
Kerrii B. Anderson, former CEO and President of Wendy's International, Inc., and Jeff M. Fettig, former Chairman and CEO of Whirlpool Corporation, join the Board CLEVELAND , April 17, 2019 /PRNewswire/ ...
Rite Aid's board clears the way for a 1-for-20 reverse stock split later this month. Booking Holdings, LabCorp, and Citi have gone on to move higher after going this route.
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of December 31. The results of that effort will be put on display in this article, as […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Laboratory Corporatio...
LabCorp® (LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019, followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 7459328. An audio replay of the conference call will be available from 1:00 p.m. EDT on April 30, 2019, until 11:30 a.m. EDT on May 14, 2019, by dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 7459328.
LabCorp® (LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of Oct. 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee (Trustee) and the conversion agent.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect score of 100 on the 2019 Corporate Equality Index (CEI), the nation’s premier benchmarking survey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human Rights Campaign (HRC) Foundation. “It is an honor to receive this recognition for a second consecutive year because of the commitment of our nearly 61,000 colleagues worldwide to creating a positive work environment and culture,” said David P. King, chairman and CEO of LabCorp.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As Laboratory Corporation of America Holdings (NYSE:LH) announced its earnings release on 31 December 2018, analyst forecasts seem fairly subdued, with profits predicted to rise by 3.6% next year againstRead More...
Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold LH had net inflows of $3.95 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LabCorp® (LH) announced today that for the period of March 11, 2019 to Sept. 10, 2019, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2019, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $2.47 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is Aug. 27, 2019. The payment of contingent cash interest is expected to be made on Sept. 11, 2019.
LabCorp® (LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 12, 2019, at 8:30 a.m. (ET). A live audio webcast of the presentation will be available via the Company website at www.LabCorp.com and archived for replay.